Trial · NCT00450437
Results by group126
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 126
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Lot to Lot Consistency of MenACWY as Measured by hSBA GMT Vaccine Group Ratios, Ages 11 to 18 Years | Novartis MenACWY Lot 1 | Serogroup A | 29 | 95% Confidence Interval 23 to 38 | Titers |
| Lot to Lot Consistency of MenACWY as Measured by hSBA GMT Vaccine Group Ratios, Ages 11 to 18 Years | Novartis MenACWY Lot 2 | Serogroup A | 33 | 95% Confidence Interval 25 to 42 | Titers |
| Lot to Lot Consistency of MenACWY as Measured by hSBA GMT Vaccine Group Ratios, Ages 11 to 18 Years | Novartis MenACWY Lot 3 | Serogroup A | 31 | 95% Confidence Interval 24 to 40 | Titers |
| Lot to Lot Consistency of MenACWY as Measured by hSBA GMT Vaccine Group Ratios, Ages 11 to 18 Years | Novartis MenACWY Lot 1 | Serogroup C (N=499, 493, 491) | 77 | 95% Confidence Interval 58 to 102 | Titers |
| Lot to Lot Consistency of MenACWY as Measured by hSBA GMT Vaccine Group Ratios, Ages 11 to 18 Years | Novartis MenACWY Lot 2 | Serogroup C (N=499, 493, 491) | 58 | 95% Confidence Interval 43 to 77 | Titers |
| Lot to Lot Consistency of MenACWY as Measured by hSBA GMT Vaccine Group Ratios, Ages 11 to 18 Years | Novartis MenACWY Lot 3 | Serogroup C (N=499, 493, 491) | 64 | 95% Confidence Interval 48 to 86 | Titers |
| Lot to Lot Consistency of MenACWY as Measured by hSBA GMT Vaccine Group Ratios, Ages 11 to 18 Years | Novartis MenACWY Lot 1 | Serogroup W (N=340, 341, 343) | 87 | 95% Confidence Interval 70 to 108 | Titers |
| Lot to Lot Consistency of MenACWY as Measured by hSBA GMT Vaccine Group Ratios, Ages 11 to 18 Years | Novartis MenACWY Lot 2 | Serogroup W (N=340, 341, 343) | 111 | 95% Confidence Interval 89 to 138 | Titers |
| Lot to Lot Consistency of MenACWY as Measured by hSBA GMT Vaccine Group Ratios, Ages 11 to 18 Years | Novartis MenACWY Lot 3 | Serogroup W (N=340, 341, 343) | 82 | 95% Confidence Interval 66 to 102 | Titers |
| Lot to Lot Consistency of MenACWY as Measured by hSBA GMT Vaccine Group Ratios, Ages 11 to 18 Years | Novartis MenACWY Lot 1 | Serogroup Y (N=345, 345, 346) | 48 | 95% Confidence Interval 37 to 62 | Titers |
| Lot to Lot Consistency of MenACWY as Measured by hSBA GMT Vaccine Group Ratios, Ages 11 to 18 Years | Novartis MenACWY Lot 2 | Serogroup Y (N=345, 345, 346) | 61 | 95% Confidence Interval 47 to 79 | Titers |
| Lot to Lot Consistency of MenACWY as Measured by hSBA GMT Vaccine Group Ratios, Ages 11 to 18 Years | Novartis MenACWY Lot 3 | Serogroup Y (N=345, 345, 346) | 53 | 95% Confidence Interval 41 to 69 | Titers |
| Percentage of Seroresponders, Ages 11 to 18 Years | Novartis MenACWY Vaccine | Serogroup A | 75 | 95% Confidence Interval 72 to 77 | Percentage of participants |
| Percentage of Seroresponders, Ages 11 to 18 Years | Licensed Meninogcoccal Vaccine | Serogroup A | 66 | 95% Confidence Interval 61 to 71 | Percentage of participants |
| Percentage of Seroresponders, Ages 11 to 18 Years | Novartis MenACWY Vaccine | Serogroup C (N= 1483, 501) | 75 | 95% Confidence Interval 73 to 77 | Percentage of participants |
| Percentage of Seroresponders, Ages 11 to 18 Years | Licensed Meninogcoccal Vaccine | Serogroup C (N= 1483, 501) | 73 | 95% Confidence Interval 69 to 77 | Percentage of participants |
| Percentage of Seroresponders, Ages 11 to 18 Years | Novartis MenACWY Vaccine | Serogroup W (N= 1024, 288) | 75 | 95% Confidence Interval 72 to 77 | Percentage of participants |
| Percentage of Seroresponders, Ages 11 to 18 Years | Licensed Meninogcoccal Vaccine | Serogroup W (N= 1024, 288) | 63 | 95% Confidence Interval 57 to 68 | Percentage of participants |
| Percentage of Seroresponders, Ages 11 to 18 Years | Novartis MenACWY Vaccine | Serogroup Y (N= 1036, 294) | 68 | 95% Confidence Interval 65 to 71 | Percentage of participants |
| Percentage of Seroresponders, Ages 11 to 18 Years | Licensed Meninogcoccal Vaccine | Serogroup Y (N= 1036, 294) | 41 | 95% Confidence Interval 35 to 47 | Percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00450437/results